Role of Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Citations of this article
Mendeley users who have this article in their library.


High-dose therapy followed by autologous stem cell transplantation (ASCT) has been the standard frontline consolidative therapy for patients with newly diagnosed multiple myeloma (MM) for > 2 decades. This approach has resulted in higher complete response (CR) rates and increased event-free survival and overall survival (OS) compared with conventional chemotherapy. The emergence of novel agent-based therapy combined with ASCT has revolutionized MM therapy by improving the CR rates and OS, raising questions concerning the role of hematopoietic stem cell transplantation in this setting.




Garcia, I. N. (2015, February 1). Role of Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. Elsevier Inc.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free